Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KNSA
BuyPremium GrowerFLAGKiniksa Pharmaceuticals International, plc · Healthcare · United Kingdom · $6.1B · Avg Vol: $42M/d
Kiniksa Pharmaceuticals has strong quality Q83 and momentum M83, but value at V20 is the lowest in this batch and far below the calibrated floor. Insider selling of 0.23% is separately adverse.
COMPANY DESCRIPTION
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics for patients with debilitating rare diseases. The company's strategic focus on underserved inflammatory and autoimmune conditions provides potential for orphan drug exclusivity, offering a strong competitive moat. Kiniksa aims to become a leader in developing targeted treatments for these specific, high-unmet-need patient populations.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 220.2M | 270.3M | 423.2M | 677.6M | 45.5% | 840.8M | 993.7M | 1.2B | 34.3% |
| EPS | -2.30 | 2.64 | 0.20 | -0.60 | 0.80 | -32.8% | 0.99 | 1.23 | — | 54.3% |
| Shares | — | 69.7M | 70.5M | 72.5M | 76.3M | +9.5% | — | — | — | — |
| Debt | — | 5.9M | 12.3M | 9.9M | 9.5M | 17.1% | 8.9M | — | — | — |
| Equity | — | 396.1M | 438.8M | 438.4M | 567.6M | 12.7% | — | — | — | — |
| Op CF | — | 5.8M | 13.3M | 25.7M | 138.0M | 187.5% | 185.0M | — | — | — |
| Inv CF | — | -8.1M | -29.6M | 37.7M | -189.0M | — | — | — | — | — |
| Fin CF | — | 2.5M | 1.5M | 12.3M | 33.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KNSA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International, plc(you) | $6.1B | 79 | Buy |
| HIK.L | Hikma Pharmaceuticals PLC | $4.5B | 94 | Strong Buy |
| HLN | Haleon plc | $44.5B | 82 | Strong Buy |
| EAH.L | ECO Animal Health Group plc | $89M | 94 | Strong Buy |
| CTEC.L | Convatec Group PLC | $6.0B | 73 | Buy |
| LIVN | LivaNova PLC | $4.4B | 83 | Strong Buy |
| SN.L | Smith & Nephew plc | $12.0B | 79 | Buy |
| AGY.L | Allergy Therapeutics plc | $489M | 3 | Strong Sell |
| GNS.L | Genus plc | $2.1B | 62 | Hold |
| SPI.L | Spire Healthcare Group plc | $1.3B | 88 | Strong Buy |
Peer medians: ROE -4.1% · P/E 24.3x · Gross margin 56.8%